Viking Therapeutics Inc. (VKTX)

8.99
NASDAQ : Health Technology
Prev Close 9.31
Day Low/High 8.91 / 9.41
52 Wk Low/High 3.67 / 24.00
Avg Volume 4.62M
Exchange NASDAQ
Shares Outstanding 71.46M
Market Cap 701.02M
EPS -0.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Viking Therapeutics Presents Results From Phase 2 Study Of VK2809 In Patients With Non-Alcoholic Fatty Liver Disease (NAFLD) And Elevated LDL-Cholesterol In Oral Late-Breaker Presentation At The Liver Meeting® 2018

Viking Therapeutics Presents Results From Phase 2 Study Of VK2809 In Patients With Non-Alcoholic Fatty Liver Disease (NAFLD) And Elevated LDL-Cholesterol In Oral Late-Breaker Presentation At The Liver Meeting® 2018

Study Achieves Primary Endpoint, Demonstrating Statistically Significant LDL-C Reductions in Patients Receiving VK2809 at Week 12

Viking Therapeutics Reports Third Quarter 2018 Financial Results And Provides Corporate Update

Viking Therapeutics Reports Third Quarter 2018 Financial Results And Provides Corporate Update

Conference call scheduled for 4:30 p.m. ET today

This Is Not Just a Market of Oversold Bounces Now

This Is Not Just a Market of Oversold Bounces Now

What is most interesting about the action today is a spike in the speculative action.

Viking Therapeutics To Report Financial Results For Third Quarter 2018 On November 7, 2018

Viking Therapeutics To Report Financial Results For Third Quarter 2018 On November 7, 2018

Conference Call Scheduled for Wednesday, November 7 at 4:30 p.m. Eastern Time

My Stock of the Week: ENDRA Life Sciences

My Stock of the Week: ENDRA Life Sciences

I'm simply focusing on individual stocks at this point and am not too concerned about the macro picture.

It Was a Very Rough Week

It Was a Very Rough Week

Just when you thought the worst was over another wave of selling would hit.

Is the Market Washed Out and Ready for Another Upcycle?

Is the Market Washed Out and Ready for Another Upcycle?

One very encouraging sign Friday is relative outperformance by names that have lately been the weakest.

CAT Stock Gets Thrown Into the Dumpster

CAT Stock Gets Thrown Into the Dumpster

This stock can become much cheaper if there is a major cycle turn occurring.

6 Steps for Dealing With a Market That Can't Be Trusted

6 Steps for Dealing With a Market That Can't Be Trusted

They include holding a high level of cash, keeping stops tight and being patient.

Netflix Is Tonight's Big Report: Here's How I Would Play It

Netflix Is Tonight's Big Report: Here's How I Would Play It

This is a battleground stock that has made big moves in both directions on earnings in the past.

Square Continues to See Extreme Pressure

Square Continues to See Extreme Pressure

If you are interested in Square longer term be patient and wait for the drama to end.

Viking Therapeutics Announces Data From In Vivo Study Of VK2809 Presented At Oral Plenary Session Of The 88th Annual Meeting Of American Thyroid Association (ATA)

Viking Therapeutics Announces Data From In Vivo Study Of VK2809 Presented At Oral Plenary Session Of The 88th Annual Meeting Of American Thyroid Association (ATA)

VK2809 Treatment Leads to Rapid Reduction in Steatosis, Inflammation and Liver Size in Mouse Model of Glycogen Storage Disease Type Ia (GSD Ia)

Viking Therapeutics Announces VK2809 Phase 2 Study Results Selected For Oral Late-Breaker Presentation At The Liver Meeting® 2018

Viking Therapeutics Announces VK2809 Phase 2 Study Results Selected For Oral Late-Breaker Presentation At The Liver Meeting® 2018

Presentation to Highlight Positive 12-Week Data for Novel, Liver-Selective Thyroid Receptor Beta Agonist in Patients with Non-Alcoholic Fatty Liver Disease and Elevated LDL-Cholesterol

There's Nothing Very Attractive About GE

There's Nothing Very Attractive About GE

It's an interesting story but there are better places for your funds.

Viking Therapeutics Presents Results From Phase 2 Study Of VK5211 In Patients Recovering From Hip Fracture In Plenary Oral Presentation At ASBMR 2018 Annual Meeting

Viking Therapeutics Presents Results From Phase 2 Study Of VK5211 In Patients Recovering From Hip Fracture In Plenary Oral Presentation At ASBMR 2018 Annual Meeting

Study Achieves Primary Endpoint, Demonstrating Statistically Significant, Dose-Dependent Increases in Lean Body Mass Ranging from 4.8% to 9.1% Following Treatment with VK5211

Viking Therapeutics To Participate In Upcoming Investor Conferences

Viking Therapeutics To Participate In Upcoming Investor Conferences

SAN DIEGO, Sept. 26, 2018 /PRNewswire/ -- Viking Therapeutics, Inc.

Viking Therapeutics Announces Pricing Of $175.8 Million Public Offering Of Common Stock

Viking Therapeutics Announces Pricing Of $175.8 Million Public Offering Of Common Stock

SAN DIEGO, Sept. 20, 2018 /PRNewswire/ -- Viking Therapeutics, Inc.

Viking Therapeutics Announces Proposed Public Offering Of Common Stock

Viking Therapeutics Announces Proposed Public Offering Of Common Stock

SAN DIEGO, Sept. 19, 2018 /PRNewswire/ -- Viking Therapeutics, Inc.

FedEx's Report Was Soft, but the Guidance Isn't Bad

FedEx's Report Was Soft, but the Guidance Isn't Bad

It is likely that value buyers will be looking for entry soon as the stock tests the $240 area.

Viking Therapeutics Announces Positive Top-Line Results From Phase 2 Study Of VK2809 In Patients With Non-Alcoholic Fatty Liver Disease (NAFLD) And Elevated LDL-Cholesterol

Viking Therapeutics Announces Positive Top-Line Results From Phase 2 Study Of VK2809 In Patients With Non-Alcoholic Fatty Liver Disease (NAFLD) And Elevated LDL-Cholesterol

Study Achieves Primary Endpoint, Demonstrating Statistically Significant Reductions in LDL-C in Patients Receiving VK2809

Six Biotechnology Names on My Watch List

Six Biotechnology Names on My Watch List

After recent weakness in the biotech sector, here are some names to start watching.

Insiders Buy The Holdings Of WMCR ETF

Insiders Buy The Holdings Of WMCR ETF

A look at the weighted underlying holdings of the Invesco Wilshire Micro-Cap ETF (WMCR) shows an impressive 19.0% of holdings on a weighted basis have experienced insider buying within the past six months. START SLIDESHOW:10 ETFs With Stocks That Insiders Are Buying » Viking Therapeutics Inc , which makes up 0.55% of the Invesco Wilshire Micro-Cap ETF (WMCR), has seen 4 directors and officers purchase shares in the past six months, according to the recent Form 4 data.

A Lesson to Learn From Thursday's Market Action

A Lesson to Learn From Thursday's Market Action

You don't have to be Sigmund Freud to understand the psychology here.

Viking Therapeutics To Participate In Upcoming Investor Conferences

Viking Therapeutics To Participate In Upcoming Investor Conferences

SAN DIEGO, Aug. 28, 2018 /PRNewswire/ -- Viking Therapeutics, Inc.

VKTX: Insiders Vs. Shorts

VKTX: Insiders Vs. Shorts

The most recent short interest data was recently released for the 08/15/2018 settlement date, and Viking Therapeutics Inc is one of the most shorted stocks of the Russell 3000, based on 7.55 "days to cover" versus the median component at 5.05. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

Viking Therapeutics Reports Second Quarter 2018 Financial Results And Provides Corporate Update

Viking Therapeutics Reports Second Quarter 2018 Financial Results And Provides Corporate Update

Conference call scheduled for 4:30 p.m. ET today

Viking Therapeutics To Report Financial Results For Second Quarter 2018 On August 9, 2018

Viking Therapeutics To Report Financial Results For Second Quarter 2018 On August 9, 2018

Conference Call Scheduled for Thursday, August 9 at 4:30 p.m. Eastern Time

Insiders Bullish On Certain Holdings Of WMCR

Insiders Bullish On Certain Holdings Of WMCR

A look at the weighted underlying holdings of the Invesco Wilshire Micro-Cap ETF (WMCR) shows an impressive 18.1% of holdings on a weighted basis have experienced insider buying within the past six months. START SLIDESHOW:10 ETFs With Stocks That Insiders Are Buying » Viking Therapeutics Inc , which makes up 0.50% of the Invesco Wilshire Micro-Cap ETF (WMCR), has seen 4 directors and officers purchase shares in the past six months, according to the recent Form 4 data.